Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Audrey Filézac de L'Étang"'
Autor:
Sara Chan, Audrey Filézac de L'Etang, Linda Rangell, Patrick Caplazi, John B Lowe, Valentina Romeo
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207619 (2018)
In situ analysis of biomarkers is essential for clinical diagnosis and research purposes. The increasing need to understand the molecular signature of pathologies has led to the blooming of ultrasensitive and multiplexable techniques that combine in
Externí odkaz:
https://doaj.org/article/0aa12233b9154fb08cea60750b6647b1
Autor:
Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella
Publikováno v:
Blood. 140:178-180
Autor:
Alessia Bottos, María José Terol, Paolo Corradini, Thomas Stauffer Larsen, Gila Sellam, Antonio Rueda Dominguez, Anna Sureda, David Carlile, Giuseppe Gritti, Anesh Panchal, Audrey Filézac de L'Étang, Francesc Bosch Albareda, Maneesh Tandon, Martin Hutchings, Yanjie Wang
Publikováno v:
Hutchings, M, Terol, M J, Bosch Albareda, F, Corradini, P, Larsen, T S, Dominguez, A R, Panchal, A, Bottos, A, Carlile, D, Wang, Y, Filézac De L'Étang, A, Tandon, M, Sellam, G & Gritti, G 2021, ' Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) ', Blood, vol. 138, no. Supplement 1, 525 . https://doi.org/10.1182/blood-2021-148359
Background: Glofit is a novel, CD20xCD3 T-cell-engaging bispecific antibody that provides monovalent binding to CD3 on T cells and bivalent binding to CD20 on B cells. As monotherapy, Glofit has shown promising response rates with manageable safety i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2921078c2fa50226647e1e33c306c1
https://portal.findresearcher.sdu.dk/da/publications/13a1d0e6-f3f3-475a-8d60-f08b91de6c6b
https://portal.findresearcher.sdu.dk/da/publications/13a1d0e6-f3f3-475a-8d60-f08b91de6c6b
Autor:
Marek Trněný, Michael Dickinson, Nancy L. Bartlett, James Relf, Michael Crump, Tycel Phillips, Linda Lundberg, David Perez-Callejo, Emmanuel Bachy, Franck Morschhauser, Audrey Filézac de L'Étang, Emma Clark, Kathryn Humphrey, Carmelo Carlo-Stella, Jan Maciej Zaucha, David Carlile
Publikováno v:
Blood. 138:130-130
Background: MCL is an aggressive non-Hodgkin lymphoma (NHL) subtype and pts with progressive disease (PD) after BTKi therapy have a poor prognosis (Martin et al. Blood 2016). Glofitamab is a T-cell-engaging, CD20xCD3 bispecific antibody with a novel